File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma

TitleSerum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma
Authors
KeywordsEnzyme linked immunosorbent assay
Esophageal squamous cell carcinoma
Neoadjuvant chemoradiation therapy
Soluble E-cadherin
Issue Date2011
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/DES
Citation
Diseases Of The Esophagus, 2011, v. 24 n. 1, p. 49-55 How to Cite?
AbstractE-cadherin is a well-documented tumor suppressor with downregulated expression in many cancer types. Upon proteolytic cleavage, a soluble form of 80-kDa degradation fragment, known as soluble E-cadherin (s-Ecad), is present in circulation; its level in sera of cancer patients is significantly associated with metastasis, recurrence, and prognosis in some malignancies. The present study investigated the association of s-Ecad with clinicopathological characteristics of patients with esophageal squamous cell carcinoma (ESCC) and its prognostic significance. A cohort of 97 patients who underwent surgery alone (n= 56) or neoadjuvant chemoradiation therapy and surgery (CRT) (n= 41) was recruited for this study. Serum samples were collected at operation (surgery group) and pre- and post-CRT treatment (CRT group) for measurement of s-Ecad protein by enzyme linked immunosorbent assay. Serum s-Ecad levels were correlated with clinicopathological parameters as well as survival. Univariate analysis showed no significant relationship between serum s-Ecad level and clinicopathological parameters for all sets of samples. Survival analysis showed that in patients who had surgical resection only, those with s-Ecad levels equal to or below the median value survived significantly longer than those with levels above the median (median survival 25.6 vs. 14.1 months, P= 0.012). Multivariate analysis showed that pathological N stage, M stage, R category, and serum s-Ecad level were significant independent prognostic factors for ESCC patients who underwent surgery only. The hazard ratio for s-Ecad was 1.104 (95% CI: 1.026-1.187) and P= 0.008. Serum s-Ecad was detected in ESCC patients and its potential as an independent prognostic marker requires further investigation. © 2010 © the Authors. Journal compilation © 2010, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.
Persistent Identifierhttp://hdl.handle.net/10722/142537
ISSN
2015 Impact Factor: 2.146
2015 SCImago Journal Rankings: 0.760
ISI Accession Number ID
Funding AgencyGrant Number
Research Grants Council of Hong Kong2/06C
Funding Information:

The authors would like to thank Mr. Ping Yin Lee for his technical assistance and statistical support. The work is funded by Central Allocation Grant (2/06C) from the Research Grants Council of Hong Kong.

References

 

DC FieldValueLanguage
dc.contributor.authorChung, Yen_HK
dc.contributor.authorLaw, Sen_HK
dc.contributor.authorKwong, DLWen_HK
dc.contributor.authorLuk, JMen_HK
dc.date.accessioned2011-10-28T02:50:43Z-
dc.date.available2011-10-28T02:50:43Z-
dc.date.issued2011en_HK
dc.identifier.citationDiseases Of The Esophagus, 2011, v. 24 n. 1, p. 49-55en_HK
dc.identifier.issn1120-8694en_HK
dc.identifier.urihttp://hdl.handle.net/10722/142537-
dc.description.abstractE-cadherin is a well-documented tumor suppressor with downregulated expression in many cancer types. Upon proteolytic cleavage, a soluble form of 80-kDa degradation fragment, known as soluble E-cadherin (s-Ecad), is present in circulation; its level in sera of cancer patients is significantly associated with metastasis, recurrence, and prognosis in some malignancies. The present study investigated the association of s-Ecad with clinicopathological characteristics of patients with esophageal squamous cell carcinoma (ESCC) and its prognostic significance. A cohort of 97 patients who underwent surgery alone (n= 56) or neoadjuvant chemoradiation therapy and surgery (CRT) (n= 41) was recruited for this study. Serum samples were collected at operation (surgery group) and pre- and post-CRT treatment (CRT group) for measurement of s-Ecad protein by enzyme linked immunosorbent assay. Serum s-Ecad levels were correlated with clinicopathological parameters as well as survival. Univariate analysis showed no significant relationship between serum s-Ecad level and clinicopathological parameters for all sets of samples. Survival analysis showed that in patients who had surgical resection only, those with s-Ecad levels equal to or below the median value survived significantly longer than those with levels above the median (median survival 25.6 vs. 14.1 months, P= 0.012). Multivariate analysis showed that pathological N stage, M stage, R category, and serum s-Ecad level were significant independent prognostic factors for ESCC patients who underwent surgery only. The hazard ratio for s-Ecad was 1.104 (95% CI: 1.026-1.187) and P= 0.008. Serum s-Ecad was detected in ESCC patients and its potential as an independent prognostic marker requires further investigation. © 2010 © the Authors. Journal compilation © 2010, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.en_HK
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/DESen_HK
dc.relation.ispartofDiseases of the Esophagusen_HK
dc.rightsThe definitive version is available at www3.interscience.wiley.com-
dc.subjectEnzyme linked immunosorbent assayen_HK
dc.subjectEsophageal squamous cell carcinomaen_HK
dc.subjectNeoadjuvant chemoradiation therapyen_HK
dc.subjectSoluble E-cadherinen_HK
dc.subject.meshCadherins - blood-
dc.subject.meshCarcinoma, Squamous Cell - blood - mortality - pathology - therapy-
dc.subject.meshEsophageal Neoplasms - blood - mortality - pathology - therapy-
dc.subject.meshEsophagectomy-
dc.subject.meshTumor Markers, Biological - blood-
dc.titleSerum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.emailLaw, S: slaw@hku.hken_HK
dc.identifier.emailKwong, DLW: dlwkwong@hku.hken_HK
dc.identifier.emailLuk, JM: jmluk@hkucc.hku.hken_HK
dc.identifier.authorityLaw, S=rp00437en_HK
dc.identifier.authorityKwong, DLW=rp00414en_HK
dc.identifier.authorityLuk, JM=rp00349en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1442-2050.2010.01093.xen_HK
dc.identifier.pmid20807231-
dc.identifier.scopuseid_2-s2.0-79551584719en_HK
dc.identifier.hkuros184618en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79551584719&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume24en_HK
dc.identifier.issue1en_HK
dc.identifier.spage49en_HK
dc.identifier.epage55en_HK
dc.identifier.isiWOS:000286214400013-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridChung, Y=22833625500en_HK
dc.identifier.scopusauthoridLaw, S=7202241293en_HK
dc.identifier.scopusauthoridKwong, DLW=15744231600en_HK
dc.identifier.scopusauthoridLuk, JM=7006777791en_HK
dc.identifier.citeulike8664484-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats